Cantargia AB (publ) (CANTA) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cantargia Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.116 Thank you. Good afternoon, everyone, and thank you for joining us. 00:00:04.116 -- 00:00:09.162 I'm Hilde Steininger, CEO of Kantarga. Today, I will present 00:00:09.162 -- 00:00:14.268 our Q1 2026 update and progress across 00:00:14.268 -- 00:00:19.374 all our IL-1 RAP1 platform, including how we are adapting 00:00:19.374 -- 00:00:25.459 our oncology strategy to an evolving treatment landscape. 00:00:25.682 -- 00:00:28.263 Next slide, please. 00:00:28.617 -- 00:00:31.822 Before we begin, I'd like to 00:00:31.822 -- 00:00:36.889 include forward-looking statements. These reflects our current expectation and involve 00:00:36.889 -- 00:00:42.237 risk and uncertainties that could cause actual outcomes to differ materially. 00:00:42.237 -- 00:00:46.884 I'd ask everyone to read this statement carefully and keep it in mind throughout the 00:00:46.884 -- 00:00:48.884 presentation. 00:00:51.711 -- 00:00:53.626 Next slide, please. 00:00:53.626 -- 00:00:58.857 I'm joined today by Patrick Remblad, our Chief Financial 00:00:58.857 -- 00:01:03.706 Officer. Together, we'll take you through the developments in the last quarter. 00:01:03.706 -- 00:01:08.937 We'll start with the strategic perspectives, then move through the portfolio, clinical 00:01:08.937 -- 00:01:12.103 updates and key financials. 00:01:12.103 -- 00:01:14.604 Next slide, please. 00:01:14.669 -- 00:01:20.078 So today I wanted to outline how we are refining our development 00:01:20.078 -- 00:01:24.645 focus across the company's core value drivers. 00:01:24.645 -- 00:01:30.014 In PDAC, recent clinical advances have increased focus to this 00:01:30.014 -- 00:01:35.263 disease area, and the treatment landscape is evolving quickly, 00:01:35.263 -- 00:01:40.555 with RAS inhibitors poised...